Valneva SE

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Valneva SE
Societas Europaea
Traded asEuronext: VLA
Fateestablished through a merger of former Intercell and Vivalis SA
Key people
Thomas Lingelbach (CEO), Frédéric Grimaud (Chairman of the supervisory board)
ProductsDevelopment of vaccines

Valneva SE is a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs. Valneva was founded in 2013 through the merger of Intercell and Vivalis SA.[1]

It has been listed on the Vienna Stock Exchange and Euronext since May 28, 2013.

Marketed vaccines generated by Valneva include Ixiaro, a vaccine against Japanese encephalitis (approved in Europe, America and Australia)[2] and Dukoral, a vaccine against cholera (approved in Europe, America and Australia)[3]

Some of its candidates have failed in clinical trials: VLA43, a therapeutic vaccine against Pseudomonas Aeruginosa,[4] V710, a therapeutic vaccine against Staphylococcus aureus (in collaboration with Merck),[5] and IC41, therapeutic vaccine against hepatitis C[6]


  1. ^ "Valneva SE company profile, wiener börse". Retrieved 2017-09-02.
  2. ^ "Ixiaro, Japanese-encephalitis vaccine (inactivated, adsorbed)". European Medicines Agency (EMA). 2009-06-05. Retrieved 2017-04-25.
  3. ^ "Dukoral, cholera vaccine (inactivated, oral)". European Medicines Agency (EMA). 2009-04-30. Retrieved 2017-04-25.
  4. ^ "Valneva writes off hospital-acquired infection vaccine following PhII/III miss". FierceBiotech, Questex LLC. 2016-09-01. Retrieved 2017-04-25.
  5. ^ "Merck ends trial of Intercell's MRSA vaccine". Reuters. 2011-06-08. Retrieved 2017-04-25.
  6. ^ "Intercell Hepatitis C Vaccine Meets Primary Endpoints". FDA News. 2007-08-22. Retrieved 2008-08-15.

External links[edit]